BR112016002401A8 - Métodos para reduzir as taxas de exacerbação de asma usando benralizumab - Google Patents

Métodos para reduzir as taxas de exacerbação de asma usando benralizumab

Info

Publication number
BR112016002401A8
BR112016002401A8 BR112016002401A BR112016002401A BR112016002401A8 BR 112016002401 A8 BR112016002401 A8 BR 112016002401A8 BR 112016002401 A BR112016002401 A BR 112016002401A BR 112016002401 A BR112016002401 A BR 112016002401A BR 112016002401 A8 BR112016002401 A8 BR 112016002401A8
Authority
BR
Brazil
Prior art keywords
benralizumab
methods
reducing
asthma
asthma exacerbation
Prior art date
Application number
BR112016002401A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016002401A2 (pt
Inventor
Ward Christine
Roskos Lorin
Wang Bing
Raible Donald
Original Assignee
Medimmune Llc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc, Astrazeneca Ab filed Critical Medimmune Llc
Publication of BR112016002401A2 publication Critical patent/BR112016002401A2/pt
Publication of BR112016002401A8 publication Critical patent/BR112016002401A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Bathtubs, Showers, And Their Attachments (AREA)
BR112016002401A 2013-08-12 2014-08-07 Métodos para reduzir as taxas de exacerbação de asma usando benralizumab BR112016002401A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361864944P 2013-08-12 2013-08-12
PCT/US2014/050080 WO2015023504A1 (en) 2013-08-12 2014-08-07 Methods for reducing exacerbation rates of asthma using benralizumab

Publications (2)

Publication Number Publication Date
BR112016002401A2 BR112016002401A2 (pt) 2017-09-12
BR112016002401A8 true BR112016002401A8 (pt) 2018-06-12

Family

ID=52448837

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002401A BR112016002401A8 (pt) 2013-08-12 2014-08-07 Métodos para reduzir as taxas de exacerbação de asma usando benralizumab

Country Status (26)

Country Link
US (2) US9441037B2 (https=)
EP (1) EP3033101B1 (https=)
JP (4) JP6746495B2 (https=)
KR (2) KR20220057637A (https=)
CN (2) CN105451760A (https=)
AU (2) AU2014306956B2 (https=)
BR (1) BR112016002401A8 (https=)
CA (1) CA2918105C (https=)
CY (1) CY1122132T1 (https=)
DK (1) DK3033101T3 (https=)
ES (1) ES2716906T3 (https=)
HK (2) HK1225302B (https=)
HR (1) HRP20190405T1 (https=)
HU (1) HUE042607T2 (https=)
LT (1) LT3033101T (https=)
ME (1) ME03348B (https=)
MX (1) MX368508B (https=)
PL (1) PL3033101T3 (https=)
PT (1) PT3033101T (https=)
RS (1) RS58404B1 (https=)
RU (1) RU2676333C2 (https=)
SG (2) SG10202005560UA (https=)
SI (1) SI3033101T1 (https=)
SM (1) SMT201900163T1 (https=)
TR (1) TR201903312T4 (https=)
WO (1) WO2015023504A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法
US9441046B2 (en) * 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab
KR20160061352A (ko) * 2013-10-15 2016-05-31 메디뮨 엘엘씨 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법
SI3060229T1 (sl) 2013-10-24 2021-11-30 Astrazeneca Ab Stabilne vodne formulacije protiteles
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
US10699274B2 (en) 2015-08-24 2020-06-30 Samsung Electronics Co., Ltd. Apparatus and method for secure electronic payment
US10846696B2 (en) 2015-08-24 2020-11-24 Samsung Electronics Co., Ltd. Apparatus and method for trusted execution environment based secure payment transactions
JP2018538249A (ja) 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
WO2018127830A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv S-arrestin peptides and therapeutic uses thereof
RU2698048C2 (ru) * 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
TW202021983A (zh) * 2018-09-21 2020-06-16 美商安納普提斯生物公司 用於嗜伊紅性氣喘之抗il-33療法
TW202214692A (zh) * 2020-06-05 2022-04-16 瑞典商阿斯特捷利康公司 治療患有鼻瘜肉的患者的重度氣喘之方法
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7404953B2 (en) 2000-02-15 2008-07-29 Kyowa Hakko Kogyo Co., Ltd. Methods using eosinophil-specific apoptosis inducer
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004279740A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Antibody composition specifically binding to IL-5 receptor
US20060014680A1 (en) 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
HUE036885T2 (hu) 2007-05-14 2018-08-28 Astrazeneca Ab Eljárás a bazofil-szint csökkentésére
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
US20110117213A1 (en) * 2009-11-18 2011-05-19 Medicinova, Inc. Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom
TWI732259B (zh) * 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
EP2710370A4 (en) * 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS
HK1201440A1 (en) 2011-11-01 2015-09-04 Medimmune, Llc Methods for reducing the frequency and severity of acute exacerbations of asthma
US9441046B2 (en) 2013-08-12 2016-09-13 Astrazeneca Ab Methods for increasing forced expiratory volume in asthmatics using benralizumab
CN111617244A (zh) * 2013-08-12 2020-09-04 阿斯特拉捷利康股份公司 使用贝那利珠单抗改善哮喘症状的方法

Also Published As

Publication number Publication date
JP2024129139A (ja) 2024-09-26
WO2015023504A1 (en) 2015-02-19
WO2015023504A8 (en) 2015-09-24
ES2716906T3 (es) 2019-06-17
DK3033101T3 (en) 2019-04-08
EP3033101B1 (en) 2018-12-19
JP2016527324A (ja) 2016-09-08
SI3033101T1 (sl) 2019-04-30
EP3033101A1 (en) 2016-06-22
HRP20190405T1 (hr) 2019-04-19
SMT201900163T1 (it) 2019-05-10
PT3033101T (pt) 2019-04-02
KR20160042121A (ko) 2016-04-18
RS58404B1 (sr) 2019-04-30
BR112016002401A2 (pt) 2017-09-12
AU2014306956A1 (en) 2016-02-04
AU2014306956B2 (en) 2019-11-21
ME03348B (me) 2019-10-20
CA2918105C (en) 2023-02-28
HUE042607T2 (hu) 2019-07-29
US9441037B2 (en) 2016-09-13
MX2016001383A (es) 2016-08-03
CA2918105A1 (en) 2015-02-19
AU2020201327A1 (en) 2020-03-12
EP3033101A4 (en) 2017-07-12
PL3033101T3 (pl) 2019-06-28
CY1122132T1 (el) 2020-11-25
JP2020128375A (ja) 2020-08-27
RU2676333C2 (ru) 2018-12-28
HK1225302B (en) 2017-09-08
MX368508B (es) 2019-10-07
KR20220057637A (ko) 2022-05-09
RU2016108723A (ru) 2017-09-19
SG10202005560UA (en) 2020-07-29
JP2022120009A (ja) 2022-08-17
TR201903312T4 (tr) 2019-04-22
US20170198049A1 (en) 2017-07-13
SG11201600481UA (en) 2016-02-26
CN105451760A (zh) 2016-03-30
HK1221644A1 (zh) 2017-06-09
US20150044202A1 (en) 2015-02-12
LT3033101T (lt) 2019-03-25
CN111588848A (zh) 2020-08-28
KR102390714B1 (ko) 2022-04-26
JP6746495B2 (ja) 2020-08-26
RU2016108723A3 (https=) 2018-06-18

Similar Documents

Publication Publication Date Title
BR112016002401A8 (pt) Métodos para reduzir as taxas de exacerbação de asma usando benralizumab
AU2014284235B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
MX2021013327A (es) Anticuerpo anti-receptor cgrp para usarse en tratar o prevenir dolor de cabeza por migra?a.
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
AR090923A1 (es) Anticuerpos anti-il-23
BR112013021863A2 (pt) anticorpos anti-receptor il-6 e métodos de uso
CL2015000352A1 (es) Métodos de tratamiento de una tauopatía
EP4406610A3 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
PH12016501366A1 (en) Novel anti-baff antibodies
AR081750A1 (es) Anticuerpos anti-cd40
MX2016002166A (es) Anticuerpos.
MX381278B (es) Composición para la estimulación ovárica controlada.
CR20130632A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
PH12016500753B1 (en) Antibodies specific to fcrn
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
MX373176B (es) Donadores de nitroxilo con indice terapeutico mejorado.
MX389103B (es) Anticuerpos contra ticagrelor y métodos de uso.
BR112016010336A2 (pt) Anticorpo anti-humano-her3 alostérico não competitivo com neuregulina, fragmento de anticorpo, sequência de ácido nucleico, vetor, célula hospedeira, composição farmacêutica e método para tratamento de câncer
BR112017002729A2 (pt) terapia de combinação para uso em um método para tratar um tumor sólido em um indivíduo, anticorpo, uso, composição farmacêutica, kit para tratar um tumor sólido, e, método para tratar um tumor sólido em um indivíduo

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25L Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled

Owner name: ASTRAZENECA AB (SE)

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA AB (SE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]